

Novel methods of continuous glucose monitoring and telehealth in the improvement of diabetes care: a narrative review

Jerzy Hohendorff¹, Leszek Czupryniak², Grzegorz Dzida³, Piotr Fichna⁴, Przemyslaw Jarosz-Chobot⁵, Tomasz Klupa¹, Malgorzata Mysliwiec⁶, Agnieszka Szadkowska⁷, Dorota A. Zozulinska-Ziolkiewicz⁸, Maciej T. Malecki¹

¹Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland

²Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland

³Department of Internal Diseases, Medical University of Lublin, Lublin, Poland

⁴Department of Pediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland

⁵Department of Children's Diabetology, School of Medicine, Medical University of Silesia, Katowice, Poland

⁶Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland

⁷Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, Lodz, Poland

⁸Department of Internal Medicine and Diabetology, Poznan University of Medical Science, Poznan, Poland

Corresponding author:

Maciej T. Malecki
Department
of Metabolic Diseases
Jagiellonian University
Medical College
Krakow, Poland
E-mail: maciej.malecki@uj.edu.pl

Submitted: 29 January 2021; **Accepted:** 15 June 2021

Online publication: 3 July 2021

Arch Med Sci 2023; 19 (3): 757–764

DOI: <https://doi.org/10.5114/aoms/139025>

Copyright © 2021 Termedia & Banach

Abstract

Standard markers of glycaemic control, such as glycated haemoglobin (HbA_{1c}) and self-measurement of blood glucose (SMBG), have proven insufficient. HbA_{1c} is an averaged measurement that does not give information about glucose variability. SMBG provides limited, intermittent blood glucose (BG) values over the day and is associated with poor compliance because of the invasiveness of the method and social discomfort. In contrast to glucometers, continuous glucose monitoring (CGM) devices do not require finger-stick blood samples, but instead measure BG via percutaneous or subcutaneous sensors. The immediate benefits of CGM include prevention of hypoglycaemia or hyperglycaemia, and automated analysis of long-term glycaemic data enables reliable treatment adjustments. This review describes the principles of CGM and how CGM data have changed diabetes treatment standards by introducing new glycaemic control parameters. It also compares different CGM devices and examines how the convenience of sharing CGM data in telehealth applies to the current coronavirus-19 pandemic.

Key words: diabetes mellitus, telehealth, continuous glucose monitoring.

Introduction

Diabetes is among the world's most common chronic diseases. It is believed that globally, nearly 1 in 10 adults have diabetes, with nearly half

a billion total patients [1, 2]. The burden of diabetes and its complications on patients, their care-takers, and healthcare systems is high [3]. Acute diabetic complications, such as severe hypoglycaemia or hyperglycaemia, may be life-threatening, whereas chronic complications can lead to substantial disability due to heart failure after myocardial infarction, loss of independence following a stroke, the need for dialysis due to kidney failure, leg amputation due to diabetic foot syndrome, or blindness due to retinopathy [4, 5].

Treatment achieving good glycaemic control can substantially reduce the risk of both acute and chronic diabetic complications [6, 7]. Currently, glycated haemoglobin (HbA_{1c}) is the most commonly used indicator of long-term glycaemic control. However, HbA_{1c} is an imperfect marker because it is a blood glucose (BG) level averaged over 3 months, and does not give information regarding the patient's target fasting or postprandial BG levels [7, 8]. Similarly, HbA_{1c} cannot reveal the frequency of hypoglycaemia or hyperglycaemia episodes, or information about glycaemic variability [9]. Self-monitoring of blood glucose (SMBG) with glucometers complements HbA_{1c} measurements by providing the patient's daily glucose levels, but gives only a limited number of glucose values per day, and is inconvenient and socially uncomfortable, which results in poor compliance and suboptimal glycaemic control [10, 11].

This review describes novel blood glucose (BG) monitoring methods, i.e., intermittently scanned continuous glucose monitoring (isCGM) and re-

al-time continuous glucose monitoring (rtCGM), which can substantially improve short-term and long-term glycaemic control and reduce the disease burden on patients and their caretakers. Both these systems are increasingly being used worldwide, so it is important that specialists in diabetology, as well as family physicians, have practical knowledge about them.

Novel methods of glucose monitoring in diabetes care

isCGM and rtCGM are new methods of monitoring BG in patients with type 1 or type 2 diabetes. In contrast to standard glucometers, isCGM and rtCGM devices do not require blood samples and, therefore, eliminate the need for multiple finger-sticks per day. This makes them not only more convenient but also a more hygienic method of glucose control. Instead, these devices use glucose sensors commonly placed percutaneously by patients themselves or, rarely, subcutaneously by medical professionals. In both methods, BG is measured continuously and non-invasively from interstitial fluid, and measurements can be read at any time [12]. In isCGM, BG readings are obtained on demand by scanning the sensor with a handheld reader or smartphone, whereas rtCGM provides constant measurements displayed on a device. Although isCGM readings are obtained on demand, the device stores 8 h of glycaemic data that are downloaded to the reader each time the sensor is scanned (Figure 1) [13]. Thus, full-day glycaemic readings are obtained by a minimum of three evenly



Figure 1. Smartphone app (FreeStyle LibreLink App) view. The device displays current blood glucose levels (1), a trend arrow (2, see interpretation on the left), and an 8-hour glycemia profile (3)

Table I. Comparison of blood glucose measurement methods*

Parameter	Self-monitoring of blood glucose with glucometer	Intermittently scanned CGM (FreeStyle Libre)	Real-time CGM (Dexcom G5, G6, Enlite/Guardian, Eversense)
Glucose level testing site	Capillary blood	Interstitial fluid	Interstitial fluid
Fingertip (or earlobe) pricking necessary to perform glucose test/calibration	With every measurement	Not required	At least twice daily (for all except Dexcom G6)
Therapeutic decisions, including those concerning insulin dosage, can be based on glucose level measurements obtained from the device	Yes	Yes	Yes: Dexcom G5, G6; No, a measurement with a glucose meter must be performed: Enlite/Guardian, Eversense
Information on dynamic changes of glucose level (glucose level trends)	No	Yes	Yes
Alerts	N/A	No: FreeStyle Libre; Yes: FreeStyle Libre2	Yes
Type of sensor	N/A	Percutaneous	Percutaneous (Dexcom, Medtronic); Implantable subcutaneous (Eversense)
Sensor operation duration	N/A	14 days	Percutaneous: 6–10 days; Subcutaneous: 180 days
On-body components	N/A	Sensor	Sensor and transmitter
Voice information on glycaemia	Selected models	Yes	No
Ketone body measurement capability	Selected models	Yes (only for Freestyle Libre reader users)	No
Approval for use in different age groups	No age limit	From the age of 4	Percutaneous: > age of 2 years (Dexcom) or no age limit (Enlite/Guardian) Subcutaneous: > age of 18 years
Approval for use in pregnancy	Yes	Yes	No: Dexcom G5, Eversense; Yes: Dexcom G6, Enlite/Guardian

*Based on the respective systems' operation manuals and manufacturers' information resources. CGM – continuous glucose monitoring.

distributed scans per day, allowing for retrospective analysis of glycaemic control. Many rtCGM devices need calibrating twice daily, requiring conventional glucose measurement with a glucometer. In contrast, the isCGM device (FreeStyle Libre) is factory calibrated, eliminating the need for finger-sticks. Table I compares the characteristics of rtCGM and isCGM with conventional glucometers.

The convenience of the novel methods of BG monitoring improves compliance and, therefore, treatment outcomes. Data from a Scottish study show that patients with diabetes rarely check their BG, against medical recommendations [14]. In contrast, large studies show that patients with type 1 or type 2 diabetes using isCGM check their glucose much more frequently: 8–16 times per day [15–17]. In patients with both major types of diabetes, fre-

quent BG monitoring is associated with better glucose control, including lower HbA_{1c} values [18, 19]. Similar findings were observed in studies in which the use of CGM devices was associated with improved glycaemic control and reduced risk of both hypoglycaemia and hyperglycaemia compared to conventional SMBG monitoring [15–17]. Within the group of patients who used isCGM, glycaemic control was better among those who scanned their sensor more frequently [15, 20]. In addition to more frequent measurements, isCGM and rtCGM provide patients with information about BG trends over short periods (e.g., 15 min). These trends are displayed as up arrows (↑), down arrows (↓), horizontal arrows (→), or angled arrows (↗, ↘), single or double, which prompt the patient to take action to avoid hyperglycaemia or hypoglycaemia (Figure 1) [21].

New parameters of glycaemic control enabled by continuous glucose monitoring

The novel methods of glucose monitoring have introduced new parameters of glycaemic control to diabetes care. HbA_{1c} monitoring combined with SMBG is insufficient for adequate glycaemic control, particularly in patients on intensive insulin therapy. Even patients with low HbA_{1c} values have an increased risk of microvascular and macrovascular diabetic complications [22], possibly because HbA_{1c} is an averaged measure, which could be the same for patients with BG ranges of 70–140 mg/dl or 40–210 mg/dl. HbA_{1c} is unable to provide information about the time spent in the target BG range, hypoglycaemia, or hyperglycaemia. Data showing full-day glycaemic coverage from isCGM or rtCGM can be used to calculate new parameters of glycaemic control such as time in range (TIR), time below range (TBR), and time above range (TAR), which are becoming new treatment targets [23]. Devices for isCGM or rtCGM provide estimates of glycaemic variability (e.g., coefficient of variation); high glycaemic variability is a risk factor for diabetic complications and should be taken into account in diabetes management [24]. Additional parameters include an estimated value of HbA_{1c}. Table II explains these new parameters of glycaemic control in more detail.

Reporting of the new parameters of glycaemic control is being standardised. Currently, a one-page Ambulatory Glucose Profile (AGP) is recommended (Figure 2), and is becoming part of routine diabetes care [25–27]. Treatment standards

Table II. Recommended standardised CGM metrics for clinical care [23]

1	Number of days CGM worn (14 days recommended)
2	Percentage of time that CGM is active (70% of data from 14 days recommended)
3	Mean glucose
4	Glucose management indicator (GMI)
5	Glycaemic variability (% coefficient of variation, %CV) target ≤ 36%
6	Time above range (TAR): % of readings and time > 250 mg/dl (> 13.9 mmol/l)
7	Time above range (TAR): % of readings and time 181–250 mg/dl (10.1–13.9 mmol/l)
8	Time in range (TIR): % of readings and time 70–180 mg/dl (3.9–10.0 mmol/l)
9	Time below range (TBR): % of readings and time 54–69 mg/dl (3.0–3.8 mmol/l)
10	Time below range (TBR): % of readings and time < 54 mg/dl (< 3.0 mmol/l)
11	Use of Ambulatory Glucose Profile (AGP) for CGM report

based on the parameters derived from CGM are in development [28].

Benefits of continuous glucose monitoring

The immediate, real-time benefits of CGM include the prevention and rapid detection of hypoglycaemia or hyperglycaemia due to more frequent measurements, device alarms, and trend arrows that prompt patients to prevent hypoglycaemia or hyperglycaemia by responding appropriately (e.g., eating a meal, increasing insulin dose). Many studies among patients with type 1 or type 2 diabetes show that CGM significantly reduces the time spent in hypoglycaemia or hyperglycaemia [16, 17, 23, 29–34]. Less time spent in dysglycaemia also decreases glycaemic variability [15]. Of note, a higher scanning frequency is associated with better glycaemic indices in patients using isCGM [15, 35].

A long-term, retrospective analysis of data from isCGM or rtCGM devices can help in the following areas:

1. Providing a general assessment of glycaemic control and identification of areas to be improved: reduced frequency and duration of hypoglycaemia/hyperglycaemia episodes; reduced BG variability and associated microvascular and macrovascular complications; reduced HbA_{1c} levels [23, 29–34, 36].
2. Identification of events responsible for episodes of hyperglycaemia or hypoglycaemia (e.g., which meals are associated with the greatest increase in the glucose level, at what time of the day and night the BG increases or decreases).
3. Assessment of the impact of physical exercise, diet, stress, or other factors on BG.

CGM offers benefits for healthcare systems as well. The data recorded by these devices can easily be shared electronically with healthcare professionals, enabling tele-consultations. The CGM devices do not require strips for measuring BG. Preventing severe episodes of hypoglycaemia or hyperglycaemia can also reduce the incidence of hospitalisation of diabetes patients [37].

The isCGM and rtCGM systems provide new, clinically relevant information on glycaemic control and address the shortcomings of HbA_{1c} monitoring alone. For example, an increased HbA_{1c} value indicates that diabetes treatment should be modified, but it does not specify which areas need to be improved (e.g., hyperglycaemia, hypoglycaemia, glycaemic variability). In contrast, new parameters of glycaemic control included in an AGP report indicate which aspects of treatment should be changed [23].

Effects of novel glucose monitoring methods on patients' everyday life

To maximize the benefits of isCGM and rtCGM, patients must be trained to use particular devices,

AGP Report

19 February 2020 - 3 March 2020 (14 Days)

LibreView

GLUCOSE STATISTICS AND TARGETS

19 February 2020 - 3 March 2020 **14 Days**

% Time CGM is Active 97 %

Ranges And Targets For	Type 1 or Type 2 Diabetes
Glucose Ranges	Targets % of Readings (Time/Day)
Target Range 70-180 mg/dL	Greater than 70% (16h 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 180 mg/dL	Less than 25% (6h)
Above 250 mg/dL	Less than 5% (1h 12min)

Average Glucose 141 mg/dL

Glucose Management Indicator (GMI) 6.7 % or 49mmol/mol

Glucose Variability 31.6 %

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES



AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.




Figure 2. Example of Ambulatory Glucose Profile showing recommended glycaemic metrics

i.e., placing percutaneous glucose sensors, using dedicated display devices and applications, and responding appropriately to BG readings and other information such as trend arrows.

Percutaneous sensors may be placed by patients themselves, which requires training. Subcutaneous sensors (Eversense) are placed by healthcare professionals in a relatively invasive procedure. Although rtCGM devices reduce the number of finger-sticks, most (all but Dexcom G6) still require a twice-daily calibration using a conventional glucometer. Conveniently, the isCGM device (FreeStyle Libre) is factory calibrated, eliminating the need for finger-sticks and the potential for errors related to faulty calibration.

An obvious advantage of CGM devices is the reduction or elimination of painful finger-sticks needed to measure BG with a glucometer. This is particularly important for children, who may not understand the concept of glycaemic control and are sensitive to pain. Parents of children with diabetes can use CGM to measure BG at night without waking their child, e.g., to rule out nocturnal hypoglycaemia, which can also improve the child's

sleep quality [38]. Checking CGM device readings is much more subtle than taking a finger-stick measurement with a glucometer; therefore patients feel more comfortable checking their BG in social situations.

CGM devices can increase both treatment compliance and disease awareness among patients with diabetes. Patients who use a CGM system check their BG much more frequently compared to conventional SMBG. Consequently, patients become more aware of their glycaemic control and are more likely to comply with their physicians' recommendations. Owing to the availability of complete glycaemic coverage, patients can identify how particular activities, meals, or stressors in their daily lives affect their BG, and the additional information guides appropriate insulin dosing.

The ability to share glycaemic data electronically offers many advantages. It can improve patient-physician cooperation and give more control over BG to caretakers of patients with diabetes.

There are some specific populations, in addition to type 1 diabetes patients, that could particularly benefit from using CGM. These populations include

children, pregnant women with diabetes and elderly patients. Generally, all patients on multiple daily injections or insulin pumps, including patients with type 2 diabetes and other specific types, reduce time spent in hypoglycaemia or hyperglycaemia, and thus have better glycaemic control. Patients with diabetes who use CGM devices report an improved quality of life and treatment satisfaction [17, 37, 39–41], reduced fear of hypoglycaemia, better work attendance [37, 42], fewer hospitalisations, and lower health-care costs [43]. As a result, there are many projections and simulations exploring the implementation of these devices in all patients with type 1 and type 2 diabetes [44–48].

Continuous glucose monitoring in telehealth

Telehealth interventions are an effective means of achieving glycaemic control in patients with diabetes [49]. CGM systems offer valuable glycaemic data that can easily be shared electronically between patients and healthcare professionals. Most CGM systems offer cloud-based platforms for sharing glycaemic data (LibreView, CareLink, Eversense DMS, Clarity). This enables a large proportion of consultations to be carried out remotely. Such tele-consultations are more convenient, less time-consuming and more cost-effective. The current pandemic of coronavirus-19 (COVID-19) has highlighted another benefit of telehealth for diabetes patients: a reduced risk of acquiring infectious disease in healthcare facilities, which are characterised by a high risk of viral transmission.

Conclusions

The novel methods to monitor BG continuously substantially improve care among patients with type 1 or type 2 diabetes. Data from CGM devices are used to facilitate better treatment compliance and outcomes and are improving routine diabetes management by providing new parameters for glycaemic control. Increased availability of CGM devices could be achieved by raising awareness among both patients with diabetes, and physicians of all clinical specialties. Subsidies should be considered for many patients worldwide, particularly because CGM systems can reduce some diabetes treatment costs by preventing hospitalisation and missed work due to diabetic complications. Data from clinical trials and observational studies showing improved glycaemic indices and quality of life should lead healthcare providers to consider wider CGM use in their patients.

Acknowledgments

We wish to thank Rafał Szot (Proper Medical Writing, Warsaw, Poland) for help with preparation of the manuscript.

This work was supported by the Abbott company (no award/grant number).

Conflict of interest

LC, GD, PJC, TK, MM, AS, DZZ, MTM received fees from Abbott, Medtronic and Roche. JH received fees from Abbott and Roche. PF received fees from Abbott.

References

1. International Diabetes Federation. IDF Diabetes Atlas. 2019. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf (accessed 1 Oct 2020).
2. Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. *Diabetologia* 2019; 62: 408-17.
3. Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. *Lancet Diabetes Endocrinol* 2017; 5: 423-30.
4. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. *Lancet Diabetes Endocrinol* 2016; 4: 537-47.
5. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388: 1545-602.
6. Glycaemic Targets: Standards of Medical Care in Diabetes – 2020. *Diabetes Care* 2020; 43 (Suppl 1): S66-76.
7. Araszkiwicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. *Clin Diabetol* 2019; 8: 1-95.
8. Aijan RA. How can we realize the clinical benefits of continuous glucose monitoring? *Diabetes Technol Ther* 2017; 19 (S2): S27-36.
9. Rayman G. Glycaemic control, glucose variability and the triangle of diabetes care. *Br J Diabetes* 2016; 16 (Suppl 1): S3-6.
10. Wagner J, Malchoff C, Abbott G. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. *Diabetes Technol Ther* 2005; 7: 612-9.
11. Vidal Florc M, Jansà Morató M, Galindo Rubio M, et al. Factors associated to adherence to blood glucose self-monitoring in patients with diabetes treated with insulin. The dapa study. *Endocrinol Diabetes Nutr* 2018; 65: 99-106.
12. Beck RW, Bergenstal RM, Laffel LM, et al. Advances in technology for management of type 1 diabetes. *Lancet* 2019; 394: 1265-73.
13. Unger J, Kushner P, Anderson JE. Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care. *Postgrad Med* 2020; 132: 305-13.
14. Cameron D, Harris FM, Evans JMM. Patterns of self-monitoring of blood glucose in insulin-treated diabetes: analysis of a Scottish population over time. *Diabetes Obes Metab* 2016; 18: 729-31.
15. Dunn TC, Xu Y, Hayter G, et al. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures:

- a European analysis of over 60 million glucose tests. *Diabetes Res Clin Pract* 2018; 137: 37-46.
16. Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Ther* 2017; 8: 55-73.
 17. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *Lancet* 2016; 388: 2254-63.
 18. Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. *Diabetes Care* 2013; 36: 2009-14.
 19. Elgart JF, González L, Prestes M, et al. Frequency of self-monitoring blood glucose and attainment of HbA1c target values. *Acta Diabetol* 2016; 53: 57-62.
 20. Jangam S, Dunn T, Xu Y, et al. Flash glucose monitoring improves glycaemia in higher risk patients: a longitudinal, observational study under real-life settings. *BMJ Open Diabetes Res Care* 2019; 7: e000611.
 21. Kudva YC, Ahmann AJ, Bergenstal RM, et al. Approach to using trend arrows in the FreeStyle Libre Flash glucose monitoring systems in adults. *J Endocr Soc* 2018; 2: 1320-7.
 22. Mongraw-Chaffin M, Bertoni AG, Golden SH, et al. Association of low fasting glucose and HbA1c with cardiovascular disease and mortality: the MESA study. *J Endocr Soc* 2019; 3: 892-901.
 23. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care* 2019; 42: 1593-603.
 24. Gorst C, Kwok CS, Aslam S, et al. Long-term glycaemic variability and risk of adverse outcomes: a systematic review and meta-analysis. *Diabetes Care* 2015; 38: 2354-69.
 25. American Diabetes Association. 6. Glycaemic Targets: Standards of Medical Care in Diabetes – 2020. *Diabetes Care* 2020; 43 (Suppl 1): S66-76.
 26. Petrie JR, Peters AL, Bergenstal RM, et al. Improving the clinical value and utility of CGM systems: issues and recommendations. *Diabetologia* 2017; 60: 2319-28.
 27. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). *Diabetes Technol Ther* 2013; 15: 198-211.
 28. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care* 2017; 40: 1631-40.
 29. Group JDRFCGMS. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. *Diabetes Care* 2010; 33: 17-22.
 30. New JP, Ajjan R, Pfeiffer AFH, et al. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). *Diabet Med* 2015; 32: 609-17.
 31. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycaemia. *N Engl J Med* 2013; 369: 224-32.
 32. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ* 2011; 343: d3805.
 33. Garg SK, Voelmler MK, Beatson CR, et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. *Diabetes Care* 2011; 34: 574-9.
 34. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycaemic control in adults with type 1 diabetes using insulin injections. *JAMA* 2017; 317: 371-8.
 35. Hohendorf J, Gumprecht J, Mysliwiec M, Zozulinska-Ziolkiewicz D, Malecki MT. Intermittently scanned continuous glucose monitoring data of polish patients from real-life conditions: more scanning and better glycaemic control compared to worldwide data. *Diabetes Technol Ther* 2021; doi:10.1089/dia.2021.0034.
 36. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. *Lancet Diabetes Endocrinol* 2019; 7: 221-30.
 37. Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycaemic control, acute admissions, and quality of life: a real-world study. *J Clin Endocrinol Metab* 2018; 103: 1224-32.
 38. Sinisterra M, Hamburger S, Tully C, et al. Young children with type 1 diabetes: sleep, health-related quality of life, and continuous glucose monitor use. *Diabetes Technol Ther* 2020; 22: 639-42.
 39. Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. *Diabetes Care* 2017; 40: 736-41.
 40. Rubin RR, Peyrot M. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump. *J Diabetes Sci Technol* 2009; 3: 1402-10.
 41. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycaemic control and treatment satisfaction in patients with type 2 diabetes. *Diabetes Care* 2019; 42: 1178-84.
 42. Patton SR, Clements MA. Psychological reactions associated with continuous glucose monitoring in youth. *J Diabetes Sci Technol* 2016; 10: 656-61.
 43. Gill M, Zhu C, Shah M, et al. Health care costs, hospital admissions, and glycaemic control using a standalone, real-time, continuous glucose monitoring system in commercially insured patients with type 1 diabetes. *J Diabetes Sci Technol* 2018; 12: 800-7.
 44. Roze S, Isitt JJ, Smith-Palmer J, et al. Long-term cost-effectiveness the dexcom g6 real-time continuous glucose monitoring system compared with self-monitoring of blood glucose in people with type 1 diabetes in France. *Diabetes Ther* 2021; 12: 235-46.
 45. Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of dexcom g6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the U.K. *Diabetes Care* 2020; 43: 2411-7.
 46. Wan W, Skandari MR, Minc A, et al. Cost-effectiveness of continuous glucose monitoring for adults with type 1 diabetes compared with self-monitoring of blood glucose: the DIAMOND randomized trial. *Diabetes Care* 2018; 41: 1227-34.
 47. Pease A, Zomer E, Liew D, Lo C, Earnest A, Zoungas S. Cost-effectiveness of health technologies in adults with

- type 1 diabetes: a systematic review and narrative synthesis. *Syst Rev* 2020; 9: 171.
48. Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. *J Diabetes Sci Technol* 2016; 10: 898-904.
49. Lee PA, Greenfield G, Pappas Y. The impact of telehealth remote patient monitoring on glycaemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials. *BMC Health Serv Res* 2018; 18: 495.